RxDoctor Payments Data

Muhammad Adam, MD

Internal Medicine · Bronx, NYNPI 1346329984

Payments from drug & device makers

$2,684in general payments, 2019–2025

Across 130 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$470
  • Merck$415
  • AbbVie$330
  • Amgen$266
  • Pfizer$250
  • Lilly USA, LLC$250
  • plus $702 from 12 others

What the payments were for

  • Food & beverage$2,54495%
  • Other$1405%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,684 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$20,757
Medicare patients
55
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel MiniEtanercept11$77,039
EliquisApixaban89$70,228
JardianceEmpagliflozin47$34,726
JanuviaSitagliptin Phosphate26$32,817
Diclofenac Sodium196$29,495
OzempicSemaglutide27$24,667
EntrestoSacubitril/Valsartan31$21,379
TrulicityDulaglutide16$21,327
VemlidyTenofovir Alafenamide14$18,604
FarxigaDapagliflozin Propanediol23$17,312
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate11$10,964
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$9,043
LinzessLinaclotide12$8,761
JanumetSitagliptin Phos/Metformin Hcl11$7,960
Lidocaine18$5,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$250$70,22889 claims
MerckJanuvia, Janumet$415$40,77737 claims
Novo NordiskOzempic$54$24,66727 claims
AstraZenecaFarxiga, Brilinta$58$22,76235 claims
NovartisEntresto$14$21,37931 claims
Lilly USA, LLCTrulicity$250$21,32716 claims
GileadVemlidy$470$18,60414 claims
AbbVieLinzess, Lumigan, Combigan$330$15,35340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →